Based on the genetic profile and clinical data of the patient, the software identifies the three most similar reference patients from an authentic historic database. The treatment, survival time and cause of death of the reference patients is displayed and serve as a decision support when choosing the optimal treatment for the patient.
Prostate cancer develops in the prostate gland. Unlike most other types of cancer, prostate cancer is slow growing in the majority of cases and only 10-15% of prostate tumors are rapidly progressing.1 Therefore, for most men diagnosed with prostate cancer the tumor does not pose a threat to the patient’s life. Usually, prostate cancer patients do not have any specific symptoms from an early stage prostate cancer. However, at later stages pain or difficulties urinating as well as problems during sexual intercourse are often experienced.
The Optimal Treatment
Less than 25 % of patients die from their prostate cancer. Nevertheless, up to 90 % receive radical treatment such as prostatectomy or radiation, although conservative strategies such as active surveillance would often be sufficient.
In current clinical practice, risk scoring systems such as D’Amico are commonly used when making a treatment decision for prostate cancer patients. However, selecting the treatment based on parameters such as Gleason Score is heavily dependent on visual assessment and human interpretation and is often challenging, particularly for patients in the intermediate risk zone.
The test can be run at any molecular pathological laboratory providing short turnover times and full control.
Prostatype® – a new gene test for prostate cancer patients
Quality of Life
Over- or Undertreatment